Sanofi, Bristol Discussing Changes To Avapro Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi and Bristol-Myers Squibb are likely to make changes to the co-promotion for the antihypertensive Avapro, Sanofi said during an Aug. 31 analysts conference call